Key result
Novel pediatric HF biomarkers lack proven utility alone, likely requiring future multimarker panels.
Why the study?
Studies of novel heart failure biomarkers in the pediatric population are scarce, and further investigation is needed for reliable prognostic and therapeutic implications.
This review summarizes novel heart failure biomarkers based on pathophysiological mechanisms and highlights the critical need for further research on their diagnostic and prognostic utility in the pediatric population.
Biomarkers should not guide pediatric HF management yet; leaves open multimarker panels for prospective validation.
Novel biomarkers of heart failure are the subject of numerous studies. Biomarkers of heart failure can be determined in the blood and in the urine. Seven groups of biomarkers of heart failure based on pathophysiological mechanisms are presented in this review, namely biomarkers of myocardial stretch, myocyte injury, myocardial remodeling, biomarkers of inflammation, renal dysfunction, neurohumoral activation, and oxidative stress. Studies of biomarkers in the pediatric population are scarce, therefore, further investigation is needed for reliable prognostic and therapeutic implications. The future of biomarker use is in multimarker panels that include a combination of biomarkers with different pathophysiological mechanisms in order to improve their diagnostic and prognostic predictive value.
No takes yet. Share an insight, caveat, or question.
Kojc et al. (2022) conducted a review in Heart failure in pediatrics. Novel biomarkers of heart failure was evaluated. Novel biomarkers of heart failure in pediatrics require further investigation for reliable prognostic and therapeutic implications, with future use likely relying on multimarker panels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: